Drug Profile
Research programme: drug discovery - AstraZeneca/Philochem AG
Latest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator Cambridge Antibody Technology; Philochem
- Developer MedImmune
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 29 Oct 2007 Cambridge Antibody Technology has been integrated into MedImmune
- 19 Apr 2007 Preclinical trials in Undefined indication in Europe (unspecified route)